|
Human adenoviral vectors |
Vaxvec ID |
35 |
Vaccine Vector Name |
Human adenoviral vectors |
Alternative Names |
HAd |
Vector VO ID |
VO_0001087
|
Advantage |
HAd5 is the best characterized of all adenoviruses (Bangari and Mittal, 2006). |
Disadvantage |
The employment of adenoviral vectors in clinical vaccine applications is thought to be limited by pre-existing immunity to the vector or immunity that rapidly develops after the first inoculation with adenoviral vectors (Bangari and Mittal, 2006). |
Safety |
Ad vectors appear to be safe for use in humans as human Ad (HAd) serotype 4 and 7 have been used as live oral vaccines in military recruits in the USA for several decades without any known adverse effects (Bangari and Mittal, 2006). |
Related Vaccine(s) |
|
References |
Bangari and Mittal, 2006: Bangari DS, Mittal SK. Development of nonhuman adenoviruses as vaccine vectors. Vaccine. 2006; 24(7); 849-862. [PubMed: 16297508].
Barouch and Nabel, 2005: Barouch DH, Nabel GJ. Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Human gene therapy. 2005; 16(2); 149-156. [PubMed: 15761255].
|
|